ArticleHIV medicine2013
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
Article in HIV medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02699736 (EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV
Who cites it
18 citing papers in PubMed.
- Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Journal of the International AIDS Society · 2017Article
- Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.Sexual health · 2017Article
- Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.Wiener klinische Wochenschrift · 2017Article
- Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- Is HIV still a special population for the treatment of hepatitis C?AIDS (London, England) · 2016Article
- Hepatitis C treatment initiation in HIV-HCV coinfected patients.BMC infectious diseases · 2016Article
- Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?World journal of hepatology · 2015Review
- HCV treatment in children and young adults with HIV/HCV co-infection in Europe.Journal of virus eradication · 2015Article
- Observational
- Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.Open forum infectious diseases · 2015Article
- Article
- Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus.Journal of translational medicine · 2014Review
- The forgotten component in the staging and management of HIV/hepatitis C virus-coinfected patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.PloS one · 2014Article
- German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.AIDS research and therapy · 2014Article
- HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study.AIDS research and therapy · 2014Article
- HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.BMC infectious diseases · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAll HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and ≥ F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe.
methodsEuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in HCV treatment uptake.
resultsA total of 1984 patients were included in the study, with a median follow-up time of 168 months [interquartile range (IQR) 121-204 months]. To date, 501 (25.3%) HIV/HCV-coinfected patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence interval (CI) 0.16-0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, falling to 3.78 (95% CI 2.50-5.07) in 2009. After adjustment, CD4 cell count > 350 cells/μL [incidence rate ratio (IRR) 1.33 (95% CI 1.06-1.67) vs. CD4 count 200-350 cells/μL] and ≥F2 liver fibrosis [IRR 1.60 (95% CI 1.14-2.25; P = 0.0065) vs. < F2 fibrosis] were predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for HCV, with fibrosis data available, had ≥F2 fibrosis and should have been considered for treatment, while only 36% of treated patients had ≥F2 fibrosis.
conclusionsAlthough treatment incidence for HCV has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.